Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stanford researcher shows flu shot benefits outweigh costs in healthy young adults

20.08.2002


Flu shots can save lives, especially among the elderly who account for most of the 20,000 flu-related deaths in the United States each year. But physicians have debated whether vaccinating healthy, younger adults is worth the time and money. The answer is yes, according to a new study based on a computer model. The study was led by Patrick Lee, MD, a resident in internal medicine at Stanford Hospital & Clinics.



"There’s been a lot of debate about optimal treatment strategies," Lee said. "Our study shows that society as a whole benefits if you vaccinate the entire population and use antiviral medications on those who get sick."

Influenza, a viral disease characterized by nasal congestion, dry cough and fever, affects 10 percent to 20 percent of the U.S. population each year, with an average of 2.8 work days lost per ill individual. Although anyone can get a flu shot, the Centers for Disease Control recommend vaccination only for specific groups, including the elderly, those with weakened immune systems and health-care workers. Most healthy adults choose not to get flu shots.


In the study, published in the Aug. 20 issue of the journal Annals of Internal Medicine, Lee and colleagues gathered previously published data on the costs and benefits of flu vaccination and treatment of flu patients with antiviral medication in healthy adults ages 18 to 50. These included costs of the vaccine and drugs, lost work time due to illness and duration of symptom relief from antiviral medications. They also surveyed 210 patients at a family practice clinic about their willingness to pay for flu symptom relief and medication without side effects.

The researchers entered this information into a computer model that subtracted the costs from the benefits to yield a net benefit or cost. They ran the model 1,000 times while systematically changing the data within known limits. For example, the cost of the flu vaccine averages $10.41 but may range from $5 to $20. For each combination of costs and benefits, the computer determined which of eight prevention and treatment strategies was most cost beneficial. The strategies included either vaccination or non-vaccination and, for those who became ill, treatment with one of three antiviral medications, including rimantadine, zanamivir and oseltamivir, or no treatment.

Using the average values for all costs and benefits, the researchers found that the four strategies that included vaccination had an overall savings of about $30 each compared to no vaccination and no treatment with antivirals. Treatment with rimantidine or zanamavir without vaccination had small savings (less than $5); treatment with oseltamivir without vaccination had a cost of 3 cents.

Lee said using a computer model may appear less rigorous because randomized clinical trials are usually the gold standard of medical research. But two previous clinical trials on the costs and benefits of flu vaccinations for healthy adults yielded widely different results. One found a savings of $46.85 per vaccination, while another found costs of $65.59 and $11.17 per vaccination over two seasons.

"Clinical trials are snapshots in time. They look at one flu season and one flu vaccine," Lee said. "In a clinical scenario where variables change over time, randomized clinical trials are not the best way to answer questions."

Using their computer model, Lee and colleagues found that a strategy that included vaccination was optimally cost-beneficial in 95 percent of their 1,000 runs. Non-vaccination became optimal when the probability of contracting the flu was less than 6.3 percent - a very mild flu season.

The study also found that treatment of flu patients with antiviral medications was optimal in 85 percent of the runs. Surprisingly, the older antiviral rimantidine was as effective as the newer drugs zanamivir and oseltamivir. But no drug emerged as a clear winner; the medications need to be compared in head-to-head tests, Lee said.

All three antiviral medications are readily available, but the United States has experienced shortages of the flu vaccine in recent years. The prevalence of different flu strains changes over time, so the two main pharmaceutical companies that manufacture the vaccine make new batches each year based on World Health Organization recommendations. In 2001, fewer than 90 million doses were available in the United States, and shipment of the vaccine to clinics was delayed.

"For most flu seasons, it is cost-beneficial for the whole society to be vaccinated. But, if there’s not enough vaccine to go around, you need to vaccinate those who need it most first," Lee said.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>